By Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
MoreBy Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019) were published in the New England Journal of Medicine. This
MoreBy Dr. Dipesh Uprety Karmanos Cancer Institute While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the activity of immunotherapy in oncogene-addicted non-small cell lung cancer is
MoreBy Dr. Tarik Hadid Wayne State University Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known hosts. There are around 200 subtypes of the virus that
MoreBy Dr. Inas Abuali Massachusetts General Hospital There is a paucity of available treatment options for patients with advanced papillary renal cancer (PRC), a disease characterized by aggressive features and a
MoreDr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the phase III AGILE trial reported in the New England Journal of Medicine, Pau
MoreBy Paolo Tarantino, MD Dana-Farber Cancer Institute/Harvard Medical School “Overall, a major shift in the way we treat breast cancer has occurred in 2022, with the demonstration that patients with tumors
MoreIn this blog article, Dr. Dan Milner, Chief Medical Officer of the American Society for Clinical Pathology, discusses his experience about his participation in the 2022 Summit on Cancer Health Disparities held
More